Patients must have histologically confirmed epithelioid hemangioendothelioma which is metastatic or locally advanced (unresectable)
Participants must have histologically confirmed melanoma that is metastatic or unresectable
Diagnosed with histologically or cytologically confirmed locally advanced/metastatic NSCLC with EGFR mutation
Have histologically confirmed unresectable or metastatic nonsquamous NSCLC and having received no prior systemic therapy for metastatic disease.
Histologically or cytologically confirmed locally advanced unresectable or metastatic adenocarcinoma of gastric or gastroesophageal junction; (for the L Cohort: no prior systemic therapy for the locally advanced or metastatic disease; for the L Cohort: disease progression during or following a first-line platinum-containing or fluoropyrimidine-containing chemotherapy regimen);
Histologically or cytologically documented locally advanced or metastatic urothelial carcinoma
Patients must have histologically confirmed MCM or ALM that is metastatic or unresectable
Histologically or cytologically confirmed adenocarcinoma of the breast with unresectable locally advanced disease, or metastatic disease and HER IHC + or + OR
Histologically or cytologically confirmed adenocarcinoma of the breast with unresectable locally advanced disease, or metastatic disease and HER IHC + or positive for HER gene amplification
Histologically or cytologically confirmed locally advanced or metastatic gastric cancer and HER IHC + or positive for HER gene amplification OR
Patients who have the below specified histologically or cytologically confirmed malignancies that have progressed to the advanced or metastatic stage.
Has histologically or cytologically confirmed metastatic, or unresectable locally advanced, recurrent NSCLC.
Histologically confirmed breast adenocarcinoma that is unresectable loco-regionally advanced or metastatic.
Histologically or cytologically confirmed locally advanced or metastatic Triple Negative Breast Cancer.
Part B: Subjects must have one of the histologically- or cytologically-confirmed unresectable (locally advanced or metastatic) solid malignancies listed below, AND have measurable disease at study entry defined by RECIST .. AND be considered suitable for treatment with pembrolizumab; in this study pembrolizumab will be considered an investigational study drug.
Patients must have a histologically confirmed metastatic and/or locally advanced sarcoma by the enrolling institution.
Histologically or cytologically confirmed diagnosis of locally advanced or metastatic ALK-positive NSCLC; at least  extracranial measurable target lesion not previously irradiated. CNS metastases allowed if asymptomatic and not currently requiring corticosteroid treatment.
Participants must have histologically or cytologically confirmed invasive breast cancer, with either locally advanced or metastatic disease; patients without pathologic or cytologic confirmation of metastatic disease should have unequivocal evidence of metastasis from physical examination or radiologic evaluation
Patients must have histologically or cytologically documented carcinoma primary to the intra- or extra-hepatic biliary system or gall bladder with clinical and/or radiologic evidence of unresectable, locally advanced or metastatic disease; patients with ampullary carcinoma are not eligible
Histologically/cytologically confirmed advanced/metastatic or unresectable solid tumors, no treatment options
Patients must have histologically or cytologically confirmed advanced or metastatic:
PHASE IB: Histologically confirmed refractory locally-advanced unresectable or metastatic pancreatic or biliary cancer
Phase : Patients with histologically or cytologically confirmed locally advanced (unresectable) or metastatic solid tumors and with progressive disease during or after treatment with a PD- or PD-L-inhibitor who meet one of the following criteria:
Patients who have histologically confirmed metastatic or unresectable GIST.
Have histologically or cytologically-documented diagnosis of advanced (metastatic and/or unresectable) thymic carcinoma, for which no curative treatment (including surgery, radiation, or other) is available
Histologically confirmed metastatic or unresectable locally advanced non-squamous NSCLC with documented EGFR mutation-positive disease
Subjects must have a histologically confirmed metastatic and/or locally advanced sarcoma
Histologically confirmed locally advanced and unresectable or metastatic melanoma
Histologically confirmed diagnosis of metastatic or locally advanced unresectable tumors
Histologically- or cytologically- confirmed locally advanced or metastatic nonfunctional well differentiated neuroendocrine tumor (WDNET)
Female patients with histologically-confirmed, unresectable locally advanced or metastatic breast cancer;
Subjects with histologically confirmed metastatic or unresectable breast cancer
Histologically or cytologically confirmed metastatic or unresectable CRC that is relapsed, refractory, or progressive following at least  prior systemic regimens in the metastatic setting.
Patients must have histologically or cytologically confirmed, inoperable or unresectable locally advanced, or metastatic NSCLC
Histologically or cytologically confirmed metastatic or unresectable locally advanced, non-squamous, NSCLC
Histologically or cytologically confirmed diagnosis of metastatic or unresectable, locally advanced, recurrent NSCLC that has been previously treated (subjects who have failed adjuvant or locally advanced therapy within  months are also eligible to participate in the study)
Patients must have histologically confirmed breast cancer that is metastatic or locally advanced and unresectable
Participants must have histologically confirmed metastatic or unresectable melanoma
Patients must have histologically or cytologically confirmed invasive breast cancer, which is recurrent, locally advanced, unresectable or metastatic
Must have histologically or cytologically documented rare tumor as defined per protocol that is metastatic or locally advanced and unresectable. Patients with locally advanced cutaneous squamous cell carcinoma that are technically resectable but in whom surgery is expected to lead to substantial function impairment or disfigurement are eligible
Subjects must have a histologically confirmed metastatic and/or locally advanced sarcoma
Histologically confirmed diagnosis of metastatic or advanced unresectable tumors that progressed on standard therapy
Histologically or cytologically confirmed adenocarcinoma of the breast with unresectable or metastatic disease
Patients with histologically confirmed locally advanced or metastatic solid carcinomas in Arm 
Patients with histologically confirmed locally advanced or metastatic colon cancer in Arm 
Patients with histologically confirmed locally advanced or metastatic cholangiocarcinomas in Arm 
Patients with histologically confirmed locally advanced or metastatic colon, gastric, ovarian, bladder cancers, as well as cholangiocarcinomas or hepatomas in Arm 
patients with a histologically confirmed diagnosis of advanced, unresectable, and/or metastatic solid tumours (any type).
Have histologically- or cytologically- confirmed unresectable or metastatic ACC that is considered incurable by local therapies
Patients must have histologically or cytologically documented carcinoma primary to the intra- or extra-hepatic biliary system or gall bladder with clinical and/or radiologic evidence of unresectable, locally advanced or metastatic disease; patients with ampullary carcinoma are not eligible
Histologically and radiologically confirmed advanced metastatic CCRCC in patients who have had at least one prior systemic therapy, which can include axitinib
Patients with histologically or cytologically-confirmed, locally advanced, or metastatic solid malignancy that is relapsed, refractory, or progressing following at least  prior systemic therapy (Part A)
Patients in Part B must have histologically or cytologically-confirmed, locally-advanced, or metastatic solid malignancy within the disease indications of Part A
ARM C COHORT : Patients must have a histologically or cytologically proven diagnosis of advanced (unresectable or metastatic) gallbladder cancer or cholangiocarcinoma and be candidates for first line therapy with gemcitabine and cisplatin
Histologically or cytologically confirmed locally advanced, inoperable, or metastatic tumors:  Carboplatin Plus Paclitaxel Arm:
Histologically or cytologically documented, incurable, unresectable locally advanced, or metastatic breast cancer
Phase II: Patients must have histologically or cytologically confirmed locally advanced, unresectable or metastatic carcinoma of the breast
Histologically-confirmed, mesothelin-expressing metastatic or advanced non-metastatic disease (tumour type specific inclusion criteria)
Histologically or cytologically confirmed diagnosis of metastatic or locally advanced unresectable tumors
Patients with histologically confirmed, locally advanced, unresectable, or metastatic solid tumors or hematological malignancies that progressed while on or after PD-/PD-L containing therapy;
Histologically or cytologically confirmed advanced (unresectable and/or metastatic) HCC
Histologically or cytologically proven metastatic or locally advanced disease. Specifically:
Patients must have histologically confirmed locally advanced or metastatic pancreas cancer
Patients must have histologically or cytologically confirmed advanced leiomyosarcoma of the uterus (ULMS); advanced ULMS is defined as metastatic ULMS or unresectable primary ULMS
-  Histologically or cytologically confirmed metastatic or unresectable locally advanced\n             NSCLC
Patients must have histologically or cytologically confirmed metastatic or unresectable locally advanced adenocarcinoma of the pancreas with no prior systemic therapy for metastatic or locally advanced disease
Study participants must have histologically or cytologically confirmed unresectable or metastatic malignant melanoma
Histologically or cytologically confirmed diagnosis of relapsed or refractory advanced or metastatic malignancies:
Histologically confirmed breast adenocarcinoma that is unresectable loco regional, or metastatic
Histologically or cytologically documented, locally advanced or metastatic NSCLC.
Subjects with histologically confirmed locally advanced or metastatic disease of the following tumor types:
Participants must have histologically or cytologically confirmed invasive breast cancer, with unresectable locally advanced or metastatic disease; participants without pathologic or cytologic confirmation of metastatic disease should have unequivocal evidence of metastasis from physical examination or radiologic evaluation
Histologically confirmed locally advanced (e.g. unresectable) or metastatic angiosarcoma that has progressed by RECIST following treatment with prior systemic treatment. . Prior pazopanib is allowed if the drug was not discontinued for toxicity (Phase  angiosarcoma cohort).
Histologically or cytologically confirmed invasive BC: incurable, unresectable, locally advanced BC previously treated with multimodality therapy or metastatic BC
Patient must have histologically or cytologically confirmed well differentiated or moderately differentiated (low grade or intermediate grade) neuroendocrine tumor that is locally advanced or metastatic and not of pancreatic origin
Postmenopausal women with histologically or cytologically confirmed locally advanced or metastatic ER positive breast cancer
Histologically confirmed inoperable locally advanced or metastatic adenocarcinoma of the stomach or GEJ which have progressed on at least  prior systemic therapy or line of treatment for unresectable/metastatic disease
Histologically confirmed unresectable advanced or recurrent esophageal cancer
A histologically or cytologically confirmed cancer that is metastatic, unresectable, or recurrent and for which treatment with ipilimumab, or nivolumab, or pembrolizumab is a reasonable therapeutic option in the opinion of the investigator.
Histologically-confirmed, locally advanced or metastatic adenocarcinoma of the breast
Females  years old and greater with histologically or cytologically confirmed diagnosis of advanced or metastatic adenocarcinoma of the breast.
Histologically-proven, unresectable, locally advanced or metastatic melanoma, SCCHN, NSCLC, and other cancers that express B-H.
Subjects with cytologically or histologically confirmed locally advanced or metastatic solid tumor malignancy
Patients must have a histologically confirmed stage IV or unresectable locally advanced adrenocortical carcinoma
Histologically or cytologically confirmed metastatic and/or unresectable progressive, well differentiated carcinoid or pancreatic neuroendocrine tumor (NET) carcinoids
Histologically or cytologically confirmed locally advanced or metastatic colon or rectal adenocarcinoma
Histologically-proven locally advanced unresectable or metastatic high colorectal carcinoma
Participants must have unresectable or metastatic histologically confirmed intrahepatic cholangiocarcinoma
Histologically confirmed PRCC, which is locally advanced or metastatic.
Patients must have histologically or cytologically documented carcinoma primary to the intra- or extra-hepatic biliary system or gall bladder with clinical and/or radiologic evidence of unresectable, locally advanced or metastatic disease; patients with ampullary carcinoma are not eligible
Patients must have histologically confirmed malignancy that is metastatic or unresectable
Phase Ib: Patients must have histologically or cytologically confirmed locally advanced renal cell carcinoma
Histologically or cytologically proven diagnosis of unresectable B thymoma or thymic carcinoma recurrent or progressing after more than one prior systemic therapy for advanced / metastatic disease
Histologically or cytologically confirmed diagnosis of metastatic or unresectable, locally advanced, recurrent NSCLC that has been previously treated (subjects who have failed adjuvant or locally advanced therapy within  months are also eligible to participate in the study)
Histologically or cytologically confirmed locally advanced, inoperable (where surgery is not indicated due to disease extension, co-morbidities, or other technical reasons), or metastatic iCCA or mixed histology tumors (combined hepatocellular-cholangiocarcinoma [cHCC-CCA])
Has histologically- or cytologically-confirmed diagnosis of locally advanced unresectable or metastatic adenocarcinoma or squamous cell carcinoma of the esophagus or advanced/metastatic Siewert type  adenocarcinoma of the esophagogastric junction (EGJ)
Cytologically or histologically and radiologically confirmed solid tumor that is inoperable, locally advanced, metastatic, or recurrent:
Histologically confirmed Papillary Renal Cell Carcinoma, which is unresectable and locally advanced or metastatic with measurable disease as per RECIST ..
Histologically or cytologically confirmed advanced metastatic or unresectable advanced colorectal cancer (CRC) or gastric cancer that is relapsed, refractory, or progressive after:
Histologically or cytologically proved diagnosis of locally advanced recurrent or metastatic non-squamous NSCLC that is not suitable for local curative treatment.
Histologically or cytologically confirmed metastatic or unresectable locally advanced/metastatic NSCLC
Part : Subjects with histologically confirmed, locally advanced or refractory TGCT (including metastatic disease) that has been deemed unresectable by an orthopedic surgeon or similar qualified personnel.
Subject has definitive histologically or cytologically confirmed locally advanced unresectable or metastatic pancreatic adenocarcinoma (islet cell neoplasms are excluded) that is measurable by RECIST Version . guidelines.
Histologically confirmed, unresectable locally advanced or metastatic transitional cell carcinoma of the urothelium
Part a, Part c, and Part f (GIST patients): Histologically confirmed locally advanced, metastatic and/or unresectable GIST.
Patients with a histologically/cytologically confirmed diagnosis of advanced and/or unresectable disease of any of the following tumors:
Histologically or cytologically confirmed locally advanced or metastatic urothelial carcinoma (UC)
Histologically or cytologically confirmed metastatic or unresectable locally advanced NSCLC with EGFR activating mutation (excluding exon  insertion); measurable disease per RECIST .
Histologically or cytologically documented unresectable, locally advanced or metastatic breast cancer or gastric cancer refractory to standard therapy.
Cytologically or histologically confirmed advanced gastric or GEJ adenocarcinoma that is metastatic or locally advanced and unresectable.
Histologically confirmed, locally advanced or metastatic HCC.
Patients must have histologically confirmed breast cancer that is:\r\n* Metastatic; OR\r\n* Incurable and locally advanced, as determined by the treating physician
DOSE ESCALATION COHORT: subjects must have histologically or cytologically confirmed sarcoma that is metastatic or unresectable
DOSE EXPANSION COHORT: subjects must have histologically or cytologically confirmed GIST that is metastatic or unresectable
Histologically or cytologically confirmed hepatocellular carcinoma that is metastatic, unresectable, or recurrent.
Histologically confirmed GIST that is locally advanced or metastatic
Histologically or cytologically confirmed, locally advanced or metastatic squamous NSCLC
Subject has histologically or cytologically confirmed metastatic or locally advanced, unresectable solid tumors harboring EGFR mutations.
Histologically or cytologically confirmed unresectable or metastatic esophagogastric adenocarcinoma
Participants with histologically or cytologically confirmed advanced metastatic or unresectable colorectal cancer (CRC) that is relapsed, refractory, or progressive following at least  prior systemic regimens in the metastatic setting.
Diagnosis of histologically-confirmed esophageal, gastric, pancreatic, or colorectal that is metastatic or locally-advanced (unresectable)
Histologically or cytologically confirmed locally advanced or metastatic adenocarcinoma of the stomach or GEJ in participants who have not received prior systemic therapy for metastatic disease
Histologically and/or cytologically proven unresectable locally advanced or metastatic tumors that express B-H on the membrane or vasculature. The requirement for previous systemic therapy may be waived if a person was intolerant of standard front-line therapy
Patients must have either \r\n* ) histologically/cytologically-confirmed borderline resectable pancreatic cancer and be prescribed neoadjuvant gemcitabine-plus-Abraxane as part of their standard of care, or \r\n* ) histologically/cytologically-confirmed locally advanced unresectable pancreatic cancer and be prescribed neoadjuvant gemcitabine-plus-Abraxane as part of their standard of care
Histologically or cytologically-confirmed advanced or metastatic GIST with a DV mutation in the PDGFRA gene as determined by central laboratory testing
